Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBAX3P)

• Drug Name: amthamine Drug Info
• Synonyms: Amthamine; 142437-67-0; 2-Amino-5-(2-aminoethyl)-4-methylthiazole; 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine; Tocris-0668; 5-(2-aminoethyl)-4-methylthiazol-2-amine; AC1L2QR3; SCHEMBL400272; ZINC5099; GTPL4025; CHEMBL293762; BDBM22881; CTK8E9579; CHEBI:92694; DTXSID80162039; AKOS006271424; RL01758; NCGC00024719-01; NCGC00024719-02; 5-Thiazoleethanamine, 2-amino-4-methyl-; KB-47389; RT-011284; FT-0694778; 2-AMINO-4-METHYLTHIAZOLE-5-ETHANAMINE; L000107; J-007652

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 126688
  ChEBI ID: CHEBI:92694
  CAS Number: CAS 142437-67-0
  TTD Drug ID: DMBAX3P

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine H2 receptor (H2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[4]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[5]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[5]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[6]
Betazole	DMUFGAY	Gastric secretory disorder	DD90	Approved	[7]
Ebrotidine	DMV5KR3	Duodenal ulcer	DA63	Withdrawn from market	[8]
Pibutidine	DMXSTRM	Ulcerative colitis	DD71	Discontinued in Phase 3	[9]
Osutidine	DMN7TL8	Duodenal ulcer	DA63	Discontinued in Phase 3	[10]
KU-1257	DMZMFX6	Duodenal ulcer	DA63	Discontinued in Phase 3	[11]
Lavoltidine	DMTY5VE	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[12]

Drug(s) Affected By Interleukin-12 subunit alpha (IL12A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[15]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[3]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[16]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[17]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[18]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[21]

Drug(s) Affected By Interleukin-12 subunit beta (IL12B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[22]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[15]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[23]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[25]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[26]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[27]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Agonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Interleukin-12 subunit alpha (IL12A)	OTDQT8GI	IL12A_HUMAN	Gene/Protein Processing	[3]
Interleukin-12 subunit beta (IL12B)	OT0JF8A3	IL12B_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4025).
• [2] N(G)-acylated aminothiazolylpropylguanidines as potent and selective histamine H(2) receptor agonists. ChemMedChem. 2009 Feb;4(2):232-40.
• [3] Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998 Nov 15;102(10):1866-73. doi: 10.1172/JCI3692.
• [4] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [5] Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
• [6] Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
• [7] Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
• [8] Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
• [9] Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
• [10] Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
• [11] Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
• [12] New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
• [13] The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis. Clin Exp Rheumatol. 2011 Nov-Dec;29(6):963-9. Epub 2011 Dec 22.
• [14] [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
• [15] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [16] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [17] Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
• [18] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [19] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [20] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [21] Transcriptomics and methylomics of CD4-positive T cells in arsenic-exposed women. Arch Toxicol. 2017 May;91(5):2067-2078. doi: 10.1007/s00204-016-1879-4. Epub 2016 Nov 12.
• [22] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [23] Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol. 2015 Dec 22;6:1452. doi: 10.3389/fmicb.2015.01452. eCollection 2015.
• [24] Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
• [25] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [26] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [27] Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001 Jun 1;97(11):3466-9. doi: 10.1182/blood.v97.11.3466.
• [28] Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. J Immunother. 2005 Jan-Feb;28(1):28-39. doi: 10.1097/00002371-200501000-00004.